Search

Cardiopulmonary resuscitation (CPR) is relatively novel branch of medical science, however first descriptions of mouth-to-mouth ventilation are to be found in the Bible and literature is full of descriptions of different resuscitation methods - from flagellation and ventilation with bellows through hanging the victims upside down and compressing the chest in order to stimulate ventilation to rectal fumigation with tobacco smoke. The modern history of CPR starts with Kouwenhoven et al. who in 1960 published a paper regarding heart massage through chest compressions. Shortly after that in 1961Peter Safar presented a paradigm promoting opening the airway, performing rescue breaths and chest compressions. First CPR guidelines were published in 1966. Since that time guidelines were modified and improved numerously by two leading world expert organizations ERC (European Resuscitation Council) and AHA (American Heart Association) and published in a new version every 5 years. Currently 2010 guidelines should be obliged. In this paper authors made an attempt to present history of development of resuscitation techniques and methods and assess the influence of previous lifesaving methods on nowadays technologies, equipment and guidelines which allow to help those women and men whose life is in danger due to sudden cardiac arrest., (© 2015 MEDPRESS.)

Strong interest in biosimilars dates back several years. In the coming years the patent protection ends for subsequent biological drugs, including monoclonal antibodies. This paper organizes the most important facts related to the issue of biosimilars. A biosimilar is a biotherapeutic product which is similar in terms of quality, efficacy and safety to an already licensed reference biotherapeutic product'. It should be noted that biosimilars approved underthe current regulations of the European Medicines Agency (EMA) meet the stringent standards of safety, efficacy and immunogenicity. It is also important to realize that the biosimilar has the right to that name, if it is registered by regulatory authorities like EMA or FDA. One should not confuse biosimilar drugs with those which counterfeit or imitate. Clinical trials on the convertibility of innovative and biosimilar drugs are ongoing. Nevertheless,there is no regulatory framework and clear guidelines of conduct in this regard. In the near future, thanks to the registration of the first biosimilar monoclonal antibodies in rheumatology and gastroenterology the availability of biological treatment for patients should increase.

In the past 2 decades tuberculosis has again become a public health priority in the world. Despite the availability of effective and inexpensive tuberculosis treatment the global tuberculosis caseload has not declined. TB is an important cause of childhood morbidity and mortality worldwide. This paper presented epidemiological situation in Poland, Europe and the world.

Acoustic rhinometry (AR) is a technique of nasal patency assessment, ever more frequently used in clinical practice. As yet, no generally accepted recommendations has been developed concerning the method of examination performing. In the paper the technique of examination is presented and the recommendations of the Committee for Standardisation of Acoustic Rhinometry, European Rhinologic Association are discussed.

On the basis of own experience from many years and literature model principles are presented of multiorgan obtaining (MOO) for transplantation. The paper describes the general principles of MOO and the basic elements of the technique of obtaining the heart, liver, and kidneys. The main purpose of the publication is to present the problems of MOO to wider circles of doctors in the context of striving to a unification of obtaining methods on the basis of the widely accepted European model.